title: Phaseolus vulgaris extract affects glycometabolic and appetite control in healthy human subjects.
abstract: Extracts of Phaseolus vulgaris (beans) are known to reduce glycaemia and food intake in rodents and humans. The present study evaluated the effects of a new, standardised and purified P. vulgaris extract (PVE), when employed as a supplement in a mixed balanced meal (60 % carbohydrates, 25 % lipids and 15 % protein), on glycometabolic and appetite control. To this end, a randomised, double-blind, placebo-controlled study was performed in twelve volunteers. Plasma glucose, insulin, C-peptide, ghrelin and satiety sensation ratings were assessed at baseline and during 3 h after meal consumption associated with PVE (100 mg) or placebo. Compared with placebo, PVE consumption resulted in lower increments in glucose (+15·4 (sem 5·4) v. 26·1 (SEM 7·3) %, P= 0·04 at 30 min), insulin (+981 (SEM 115) v. 1325 (SEM 240) %, P= 0·04 between 45 and 120 min) and C-peptide (+350 (SEM 27) v. 439 (SEM 30) %, P= 0·04 between 30 and 90 min). In the first 2 h, plasma ghrelin decreased similarly in both groups but did not rebound as in placebo thereafter (P= 0·04). Correspondingly, satiety sensation in the third hour was significantly reduced in the placebo but not in the PVE condition. PVE induced a lower desire to eat than placebo (P= 0·02) over the 3 h. In conclusion, PVE supplementation reduced postprandial glucose, insulin and C-peptide excursions, suppressed ghrelin secretion and affected satiety sensations, inducing a lower desire to eat. These results support that further studies are needed to prove the concept of employing PVE as a supplement in mixed balanced meals in obese, glucose-intolerant and diabetic subjects.
authors.affiliation: Department of Food, Environmental and Nutritional Sciences, International Center for the Assessment of Nutritional Status, Università degli Studi di Milano, Via Celoria 2, 20133 Milan, Italy. angela.spadafranca@unimi.it
authors.forename: Angela
authors.initials: A
authors.lastname: Spadafranca
authors.forename: Samuele
authors.initials: S
authors.lastname: Rinelli
authors.forename: Antonella
authors.initials: A
authors.lastname: Riva
authors.forename: Paolo
authors.initials: P
authors.lastname: Morazzoni
authors.forename: Paolo
authors.initials: P
authors.lastname: Magni
authors.forename: Simona
authors.initials: S
authors.lastname: Bertoli
authors.forename: Alberto
authors.initials: A
authors.lastname: Battezzati
mesh_terms: D000328:Adult; D001069:Appetite Regulation / Q000187:drug effects*; D001786:Blood Glucose / Q000378:metabolism*; D002097:C-Reactive Protein / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy; D004032:Diet; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D054439:Ghrelin / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male; D009765:Obesity / Q000097:blood / Q000188:drug therapy; D027805:Phaseolus; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology* / Q000627:therapeutic use; D019518:Postprandial Period; D012016:Reference Values; D012527:Satiation / Q000187:drug effects; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D054439:Ghrelin; D007328:Insulin; D010936:Plant Extracts; D002097:C-Reactive Protein